LUND, Sweden, Dec. 4, 2020 /PRNewswire/ -- Alligator
Bioscience (Nasdaq Stockholm: ATORX) today announced an
approved IND (Investigational new Drug) for the CD40 targeting
antibody mitazalimab. IND approval by the US Food and Drug
Administration (FDA) is a prerequisite to start clinical trials in
the USA. Recently, new benchmark
data was published showing that mitazalimab has the potential to be
best-in-class in the CD40 field. The comparison demonstrated the
potent immune-activating properties and anti-tumor effects of
mitazalimab.
"While the upcoming clinical Phase Ib/II study in pancreatic
cancer, OPTIMIZE-1, will be starting in Europe, the IND opens up for later expansion
in the US. This is essential for the future success of the
product", said Per Norlén, CEO of Alligator Bioscience.", said Per
Norlén, CEO of Alligator Bioscience. "Our key focus right now is to
complete the submission of the CTA for start of OPTIMIZE-1 in the
EU", he added.
The mitazalimab drug candidate has previously reported positive
clinical data from a Phase I study performed by Janssen Biotech
Inc., displaying a manageable safety profile as well as early signs
of efficacy.
For further information, please contact:
Cecilia Hofvander, Director
Investor Relations & Communications
Phone +46 46 540 82 06
E-mail: cecilia.hofvander@alligatorbioscience.com
The information was submitted for publication, through the
agency of the contact person set out above, at 9:00 a.m. CET
on December 4, 2020.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology
company developing tumor-directed immuno-oncology antibody drugs.
Alligator's pipeline includes the two key assets ATOR-1017 and
mitazalimab. Furthermore, there are two partnered assets:
ALG.APV-527 in co-development with Aptevo Therapeutics Inc. and
AC101 in clinical development by Shanghai Henlius Biotech Inc.). In
addition, the company has developed a novel concept for more
patient-specific immunotherapy: Neo-X-Prime. Alligator's shares are
listed on Nasdaq Stockholm (ATORX). The Company is headquartered in
Lund, Sweden. For more
information, please visit www.alligatorbioscience.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/alligator-bioscience/r/approved-ind-for-alligator-bioscience-s-cd40-targeting-antibody-mitazalimab,c3249146
The following files are available for download:
https://mb.cision.com/Main/12681/3249146/1344206.pdf
|
Approved IND for
Alligator Bioscience’s CD40-targeting antibody
mitazalimab
|
View original
content:http://www.prnewswire.com/news-releases/approved-ind-for-alligator-biosciences-cd40-targeting-antibody-mitazalimab-301186398.html
SOURCE Alligator Bioscience